78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details

臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

463 trials found

diseases per page:

Showing 1 to 10 of 463 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05509894 (ClinicalTrials.gov)	November 2023	19/8/2022	Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric P ...	Post Marketing Surveillance (PMS) Study for Ngenla® Pre-filled Pen in Pediatric Patients Who Have Gr ...	Pediatric Growth Hormone Deficiency	Drug: Ngenla	Pfizer	NULL	Not yet recruiting	3 Years	19 Years	All	565		NULL
2	NCT05355272 (ClinicalTrials.gov)	June 2023	20/4/2022	Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)	Growth HormoneReplacement Therapy in Veterans With Gulf War Illness and Adult Growth HormoneDeficien ...	Gulf War Syndrome;Adult Growth Hormone Deficiency	Drug: Recombinant human growth hormone;Drug: Placebo	Baylor College of Medicine	United States Department of Defense	Not yet recruiting	18 Years	64 Years	All	36	Phase 2	United States
3	NCT04867317 (ClinicalTrials.gov)	May 1, 2023	8/4/2021	Growth HormoneReplacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Grow ...	CSP #2018 - Growth HormoneReplacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) an ...	Adult Growth Hormone Deficiency;Mild Traumatic Brain Injury	Drug: Somatropin;Other: Placebo	VA Office of Research and Development	NULL	Not yet recruiting	21 Years	55 Years	All	172	Phase 3	United States
4	NCT05602766 (ClinicalTrials.gov)	February 6, 2023	27/10/2022	Ngenla Subcutaneous Injection Special Investigation	Ngenla® Subcutaneous Injection Special Investigation	Growth Hormone Deficiency Without Epiphyseal Closure	Drug: NGENLA (Somatrogon)	Pfizer	NULL	Recruiting	N/A	15 Years	All	229		Japan
5	NCT05718570 (ClinicalTrials.gov)	February 3, 2023	30/1/2023	A Study to Follow Patients With Adult Growth HormoneDeficiency (AGHD) Treated With Sogroya® for Long ...	A Multi-national, Multi-centre, Prospective, Single-arm, Observational, Non-interventional Post-auth ...	Adult Growth Hormone Deficiency	Drug: Somapacitan	Novo Nordisk A/S	NULL	Recruiting	18 Years	N/A	All	400		Slovenia
6	NCT05660356 (ClinicalTrials.gov)	February 2023	13/12/2022	Growth Hormone Deficiency in Mild Traumatic Brain Injury	Growth Hormone Deficiency in Patients With Persistent Symptoms Following Concussion	Growth Hormone Treatment;Growth Hormone Deficiency;Concussion, Mild;Concussion Post Syndrome	Drug: Growth Hormone;Drug: Placebo	University of Calgary	Pfizer	Not yet recruiting	18 Years	65 Years	All	20	Early Phase 1	NULL
7	EUCTR2021-004313-39-GR (EUCTR)	17/06/2022	18/04/2022	An extension study to check the safety of once weekly lonapegsomatropin when given for a long time i ...	A Multicenter, Open-Label, Extension Trial to Investigate Long TermEfficacy and Safety of Lonapegsom ...	Adult Growth HormoneDeficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;Te ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: Lonapegsomatrop ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Au ...
8	EUCTR2018-001989-42-SI (EUCTR)	05/05/2022	05/05/2021	A research study of how well macimorelin works to find out if children have a lack of growth hormone ...	Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg ...	Diagnosis of growth hormonedeficiency in pediatric subjects;Therapeutic area: Analytical, Diagnostic ...	Trade Name: Macimorelin Consilient Health Product Name: Macimorelin Product Code: AEZS-130 INN or Propos ...	Aeterna Zentaris GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Serbia;Czechia;Slovenia;Poland;Ukraine;Romania;Russian Federation;Georgia;Germany;Unit ...
9	EUCTR2018-001989-42-DE (EUCTR)	02/05/2022	07/05/2021	A research study of how well macimorelin works to find out if children have a lack of growth hormone ...	Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg ...	Diagnosis of growth hormonedeficiency in pediatric subjects;Therapeutic area: Analytical, Diagnostic ...	Trade Name: Macimorelin Consilient Health Product Name: Macimorelin Product Code: AEZS-130 INN or Propos ...	Aeterna Zentaris GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Serbia;Czechia;Slovenia;Poland;Ukraine;Romania;Russian Federation;Georgia;Germany;Ital ...
10	EUCTR2020-000929-42-NL (EUCTR)	14/04/2022	23/02/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth HormoneDeficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;Te ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATROP ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Turkey;Israel;United Kingdom;Italy;France ...

First Previous1 2 3 4 5…47Next Last